{\rtf1\ansi\ansicpg1252\cocoartf949\cocoasubrtf430
{\fonttbl\f0\froman\fcharset0 TimesNewRomanPSMT;\f1\fswiss\fcharset0 ArialMT;}
{\margl1800\margr1600\margt500\margbl1440}
{\pard\sa900\fs50\f0\i Media Release\par}
{\pard\f0\li0\ri0\sa360\sl360\fs22 Basel, 23 October 2003 \line \line {\b Roche and Nippon 
Shinyaku enter alliance to develop new medicines to treat cardiovascular disorders} \line Novel 
compounds to be developed for improved control of blood lipids\par}{\pard\f0\li0\ri0\sa360\sl360\fs22 Basel, Switzerland 
and Tokyo, Japan - Roche and Nippon Shinyaku Co., Ltd. today announced a strategic alliance to develop 
drug candidates for the treatment of blood lipid dysfunction (dyslipidemia), a condition that results 
in abnormal lipid and lipoproteins levels in the blood stream, leading to a significant increased risk 
of cardiovascular disease (CVD). The lead drug candidate NS-220 has proven to be a potent controller 
of the levels of both triglycerides and High Density Lipoproteins, HDL, and is expected to enter Phase 
I clinical trials in 2004. NS-220 adds an important new program to the Roche research and development 
portfolio which could produce the first of a novel class of cardiovascular drugs.\par}{\pard\f0\li0\ri0\sa360\sl360\fs22 \u8220?We 
believe that raising HDL levels is the next frontier in cholesterol management. This alliance with Nippon 
Shinyaku is especially important since no satisfactory drugs in this class currently exist on the market. 
With NS-220, we have a very promising drug candidate with which to pursue this next breakthrough class,\u8221? 
stated William M. Burns, Head of Roche\u8217?s Pharmaceuticals Division. \par}{\pard\f0\li0\ri0\sa360\sl360\fs22 \u8220?NS-220 
is a promising compound as an HDL up-regulator and we expect that NS-220 will make a substantial contribution 
to the treatment of dyslipidemia. Roche is a world leading healthcare company with expertise and experience 
in the cardiovascular field and is the best suitable partner for the development of NS-220. We are very 
glad to have this strategic alliance with Roche,\u8221? stated Kazuto Hatsuyama, President, Nippon Shinyaku 
Co., Ltd.\line \line {\b Terms of the Agreement} \line Under 
the terms of the agreement, Roche will have exclusive rights in the U.S. and Europe to market any drug 
resulting from the agreement. Nippon Shinyaku will have rights to co-develop and co-market in Japan, 
People\u8217?s Republic of China including Hong Kong, Republic of Korea and Taiwan. Roche will pay Nippon 
Shinyaku milestone payments and royalties based on product sales. \par}{\pard\f0\li0\ri0\sa360\sl360\fs22 {\b About 
NS-220} \line In preclinical trials, NS-220 has proven to be a potent and highly selective 
Peroxisome Proliferator-Activated Receptor alpha ({\b PPARa} ) agonist that exhibits greater 
efficacy in controlling the levels of both triglycerides and HDL than currently marketed treatments 
for dyslipidemia. PPAR agonists are known to exert beneficial effects in dyslipidemia patients by increasing 
the expression of the major apolipoproteins in HDL and by augmenting the clearance of plasma triglycerides. 
The increased clearance and decreased production rates of triglyceride-rich lipoproteins, in addition 
to a marked increase in fatty acid oxidation, suggest that NS-220 could be a treatment of choice for 
secondary dyslipidemia in patients with diabetes as well.\par}{\pard\f0\li0\ri0\sa360\sl360\fs22 Besides its usefulness 
in cardiovascular therapy, NS-220 is also under investigation as a treatment for secondary dyslipidemia 
in patients with diabetes, an area of particular interest to Roche. Roche\u8217?s Xenical is the world's leading 
medicine for weight loss and weight control, and was approved for expanded use in treating overweight 
Type 2 diabetics who are also being treated with one or more oral antidiabetic medicines.\par}{\pard\f0\li0\ri0\sa360\sl360\fs22 {\b Epidemiology} \line Cardiovascular 
diseases remain the number one killer in western countries, currently affecting over 59.7 million Americans. 
In addition to CVD, there is an increasing prevalence and medical need for lipid-modifying drugs in 
obese and Type 2 diabetic patients. As many as 90% of the about 14 million Type 2 diabetic patients 
in the US are overweight or obese and a high proportion of Type 2 diabetic patients have abnormal concentrations 
of lipoproteins. In the US, Japan and Europe there are more than 240 million people with abnormal lipoprotein 
levels. Of these, more than 55 million have low high density lipoprotein (HDL) and/or high triglyceride 
levels. \par}{\pard\f0\li0\ri0\sa360\sl360\fs22 {\b Roche in Cardiovascular and Metabolic Diseases} \line Roche 
is committed to finding novel and more effective medicines to treat and manage cardiovascular diseases, 
especially in areas where few treatment options exist. NS-220 will join a strong cardiovascular portfolio, 
with products that includes: Bumex (bumetanide), for edema associated with congestive heart failure 
and renal disease; Cardene (nicardipine HCl), for chronic stable angina, Demadex (torsemide), for edema 
associated with congestive heart failure, renal disease or hepatic disease and Dilatred (carvedilol) 
for haemodynamic balance in hypertension, heart failure and ischaemic heart disease. \par}{\pard\f0\li0\ri0\sa360\sl360\fs22 Additionally, 
Roche is a leading supplier of products and services for diabetes monitoring and integrated diabetes 
management. In 2002, Roche Diabetes Care, a business area of Roche Diagnostics, posted sales of 2.5 
billion Swiss francs (+14% in local currencies), thanks to the continued success of the Accu-Chek product 
line. \par}{\pard\f0\li0\ri0\sa360\sl360\fs22 {\b Roche Business Development and Alliance Strategy } \line Roche 
is a distinctive alliance partner with expertise in identifying cutting-edge innovation that can lead 
to new and improved medicines. During the past 18 months, Roche has formed over 45 new partnerships 
which span a wide range of therapeutic areas and technologies, making it an industry leader. Through 
its alliance strategy, Roche creates value with its partners by transforming these business transactions 
into productive relationships. \par}{\pard\f0\li0\ri0\sa360\sl360\fs22 This partnership with Nippon Shinyaku marks 
the second licensing deal Roche has signed with a Japanese company in the last five months, in addition 
to its innovative strategic partnership with Chugai Pharmaceutical Co., Ltd. Roche recognizes the valuable 
scientific research and opportunities emerging from Japanese pharmaceutical companies and is actively 
pursuing further relationships within Japan and across the globe.\par}{\pard\f0\li0\ri0\sa360\sl360\fs22 {\b About 
Roche } \line Headquartered in Basel, Switzerland, Roche is one of the world\u8217?s leading 
innovation-driven healthcare groups. Its core businesses are pharmaceuticals and diagnostics. Roche 
is number one in the global diagnostics market, the leading supplier of pharmaceuticals for cancer and 
a leader in virology and transplantation. As a supplier of products and services for the prevention, 
diagnosis and treatment of disease, the Group contributes on a broad range of fronts to improving people\u8217?s 
health and quality of life. Roche employs roughly 65,000 people in 150 countries. The Group has alliances 
and R&D agreements with numerous partners, including majority ownership interests in Genentech and 
Chugai. \par}{\pard\f0\li0\ri0\sa360\sl360\fs22 {\b About Nippon Shinyaku Co., Ltd.} \line Founded 
in the ancient capital Kyoto in 1919, Nippon Shinyaku is an R&D-oriented pharmaceutical company 
specializing in the development, manufacturing and sales of ethical pharmaceuticals. Through the sales 
of remedies for prostatic hypertrophy and frequent urination, Nippon Shinyaku has built a reputation 
as a pharmaceutical company specialized in the urological field. Nippon Shinyaku also has developed 
new chemical entities in gastrointestinal, cardiovascular and allergy & inflammation fields and 
so on and, in addition, has penetrated the functional food field. Nippon Shinyaku employs roughly 1750 
people and annual business sales amount is about 53 billion yen. For more information, access the website. 
\par}{\pard\f0\li0\ri0\sa360\sl360\fs22 All trademarks used or mentioned in this release are legally protected.\par}{\pard\f0\li0\ri0\sa360\sl360\fs22 {\b Conditions} \line The 
transaction may be subject to review by Federal Trade Commission under the Hart-Scott-Rodino Antitrust 
Improvements Act of 1976.\par}
{\pard \par}
{\pard\sb180\f1\fs22 {\b F. Hoffmann-La Roche Ltd}\line 4070 Basel\line Switzerland \par}
{\pard\sb180\f1\fs22 Corporate Communications\line Roche Group Media Relations \par}
{\pard\sb180\f1\fs22 Tel. +41 61 688 88 88\line Fax +41 61 688 27 75\line www.roche.com \par}
}